Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
Rhea-AI Summary
Senti Bio (Nasdaq: SNTI) participated in the Cell & Gene Live virtual event on February 19, 2026, presenting its Gene Circuit platform and Logic-Gated SENTI-202 approach.
According to the company, the presentation discussed how Gene Circuit design aims to enhance precision, control, and functionality in engineered cell therapies; a recording is available on demand.
Positive
- None.
Negative
- None.
Market Reality Check
Peers on Argus
Peer performance is mixed: some biotech peers are notably lower (e.g., LSB -20.62%, LVTX -3.87%) while others are modestly higher (e.g., MRSN +0.62%, IPSC +3.88%). Scanner activity shows only one peer in momentum, suggesting this event-related headline aligns more with company-specific visibility than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Clinical trial update | Positive | -1.9% | Completed enrollment in Phase 1 SENTI-202 AML trial with prior positive data. |
| Feb 03 | Conference appearance | Positive | -3.0% | On-stage presentation at Healthcare Conference Taipei 2026 on Gene Circuit platform. |
| Jan 14 | Investor presentation | Positive | +3.8% | Virtual CEO segment discussing AML data and RMAT designation for SENTI-202. |
| Jan 09 | Panel participation | Positive | +2.8% | CEO panel at Biotech Showcase on advances in cell and gene therapies. |
| Dec 18 | Inducement grant | Neutral | +2.6% | Announcement of stock option grant to a new employee under inducement plan. |
Recent event and conference-related news often saw modest price moves, with a mix of alignment and divergence between positive headlines and subsequent trading.
Over the past few months, Senti Biosciences highlighted clinical and visibility milestones around its Gene Circuit and SENTI-202 programs. On Feb 11, 2026, completion of Phase 1 enrollment for SENTI-202 and prior positive ASH data coincided with a -1.88% move. Multiple conference and panel participations in early 2026, plus an employment inducement grant on Dec 12, 2025, produced small up or down reactions. This Cell & Gene Live participation continues a pattern of outreach and platform visibility without new trial or financial data.
Market Pulse Summary
This announcement highlights Senti Biosciences’ role in a Cell & Gene Live webinar, emphasizing its Gene Circuit-based, logic-gated approach to engineered cell therapies and the SENTI-202 product. It continues a series of visibility and thought-leadership events following recent clinical and regulatory milestones. With prior SEC filings outlining operating losses and financing discussions, investors may focus less on this non-data event and more on upcoming clinical progress and capital planning as key drivers to watch.
Key Terms
gene circuit technical
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Cell & Gene Live virtual event focused on emerging and enabling technologies designed to advance the development of innovative cell therapies.
The Cell & Gene Live webinar, held on February 19, 2026, convened industry leaders and innovators to discuss approaches aimed at improving the design, development and translation of cell therapies. The Company shared perspectives on how its Gene Circuit-based approach is designed to enable enhanced precision, control, and functionality in engineered cell therapies.
“We were thrilled to be invited to participate in this Cell & Gene Live event and to engage in a thoughtful discussion around cutting-edge technologies shaping the future of cell therapy development, such as our Logic-Gated SENTI-202 product,” said Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences. “Forums like this are critical for sharing perspectives across the industry as we collectively work to advance more precise and effective therapeutic solutions for patients with our unique Logic-Gated cell therapies.”
A recording of the Cell & Gene Live event is available on demand and can be accessed here.
About SENTI-202
SENTI-202 is the first Logic Gated off-the-shelf CAR-NK cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, such as AML and myelodysplastic syndrome (MDS), while sparing healthy bone marrow cells. SENTI-202 has three main components. First, SENTI-202 contains an OR GATE, which is an activating CAR that recognizes and kills CD33 and FLT3 expressing cells. By targeting either or both of these antigens, SENTI-202 is designed to effectively kill both leukemic blasts (that largely express CD33) and leukemic stem cells (that predominantly express FLT3), which constitute a difficult-to-eradicate reservoir of AML disease. Second, SENTI-202 contains a NOT GATE, which is an inhibitory CAR that is designed to recognize EMCN selectively expressed on healthy hematopoietic stem and progenitor cells and protect those healthy cells from being killed even if they express CD33 and/or FLT3, thus potentially widening the therapeutic window. Third, SENTI-202 contains calibrated-release IL-15, which is designed to significantly increase cell persistence, expansion and activity of both the CAR-NK cells and host immune cells. The NK cells used to construct SENTI-202 are sourced from selected healthy adult donors, manufactured, cryopreserved and available off-the-shelf for use as needed. Senti Bio is currently enrolling adult patients with R/R CD33 and/or FLT3 expressing heme malignancies in a Phase 1 clinical trial for SENTI-202, which can be a potential first-in-class allogeneic treatment for AML/MDS patients.
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML.
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline comprises cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
FAQ
What did Senti Bio (SNTI) present at the Cell & Gene Live event on February 19, 2026?
How does Senti Bio (SNTI) describe the benefits of its Gene Circuit platform?
When and where was the Cell & Gene Live webinar that featured Senti Bio (SNTI)?
Is a recording of Senti Bio's (SNTI) Cell & Gene Live presentation available to watch?
What is SENTI-202 and how was it referenced by Senti Bio (SNTI) at the event?
